Video

Dr. Natale on the Evolution of Immunotherapy in NSCLC

Author(s):

Ronald Natale, MD

In Partnership With:

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

Ronald B. Natale, MD, medical director of the Clinical Lung Cancer Program and assistant clinical professor of medicine at Cedars-Sinai, discusses the evolution of immunotherapy in advanced non–small cell lung cancer (NSCLC).

Over the past 2 years, the role of immunotherapy in NSCLC has evolved from approvals for second-line treatment in advanced stage IV disease. Since then, results from randomized clinical trials have demonstrated that both nivolumab (Opdivo) and pembrolizumab (Keytruda) are more effective than docetaxel, but with those data, the immune checkpoint inhibitors have quickly moved into the first-line setting, explains Natale.

The first group of studies in this field were done with immune checkpoint inhibitors versus standard first-line chemotherapy. Results have indicated that, in patients with a high tumor proportion score of PD-L1, which constitutes about 25% to 30% of the patient population,single-agent pembrolizumab was superior to standard platinum-based chemotherapy in those with squamous or NSCLC, concludes Natale.

Related Videos
Yuan Yuan, MD, PhD
Yuan Yuan, MD, PhD
Jun Gong, MD
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Stephen J. Freedland, MD
Anthony T. Nguyen, MD, PhD, faculty member, Department of Radiation Oncology, Cedars-Sinai Cancer Institute
Related Content
Julie R. Brahmer, MD, MSc, FASCO, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
November 6th 2024

Brahmer's Take: Advancements in 3 Cornerstone Settings of NSCLC

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California, as well as a health sciences clinical professor at the University of California, Los Angeles
October 8th 2024

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California. She is also a health sciences clinical professor at the University of California, Los Angeles.
October 5th 2024

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests

Jonathan D. Spicer, MD, PhD, FRCS, of McGill University Health Centre
September 15th 2024

Perioperative Nivolumab Shows EFS Benefit vs Placebo in Resectable NSCLC